Apogee Therapeutics, Inc. — Form 8-K
Filed September 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Apogee Therapeutics entered into a Merger Agreement dated June 18, 2026 with AbbVie Inc., whereby AbbVie will acquire Apogee through Andor LLC and Andor Merger Co. The filing includes amended corporate governance documents (Certificate of Incorporation and Bylaws) and a 280G Gross-Up Payment Agreement template capping total tax gross-ups at $12.5 million across named executives. No specific deal valuation is disclosed in these exhibits, but the transaction constitutes a change of control triggering severance and tax-gross-up obligations.
Why this rating
Acquisition by large pharma peer (AbbVie) is transformational for $1.8B company; changes ownership/control, triggers change-of-control benefits, and likely represents material exit event for shareholders and employees.
Tradability signal
NO TRADE
No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +1.44% over 4 hrs, n=1).
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $135.07 | +10 min · unknown $135.07 ▲ 0.00% | +30 min · unknown $135.07 ▲ 0.00% | +1 hr · unknown $135.07 ▲ 0.00% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.